Patents by Inventor Bert W. O'Malley

Bert W. O'Malley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • System for regulation of transgene expression
    Publication number: 20030220286
    Abstract: Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.
    Type: Application
    Filed: March 25, 2003
    Publication date: November 27, 2003
    Inventors: Ronald V. Abruzzese, Vidya Mehta, Jeffrey L. Nordstrom, Jason Fewell, Bert W. O'Malley, Sophia Y. Tsai
  • Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
    Patent number: 6635447
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product. The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: October 21, 2003
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
    Patent number: 6599698
    Abstract: The present invention provides mutant proteins of steroid hormone receptors. These mutant proteins are useful in methods of distinguishing a steroid hormone receptor antagonist from a steroid hormone receptor agonist. The present invention also provides plasmids containing mutated steroid hormone receptor proteins and cells transfected with those plasmids. In addition, the present invention provides methods for determining whether a compound is a steroid hormone receptor antagonist or agonist. Also, the present invention provides methods of determining endogenous ligands for steroid hormone receptors. The invention further provides a molecular switch for regulating expression in gene therapy and methods of employing the molecular switch in humans, animals, transgenic animals and plants.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: July 29, 2003
    Assignee: Baylor College of Medicine
    Inventors: Elisabetta Vegeto, Donald P. McDonnell, Bert W. O'Malley, William T. Schrader, Ming-Jer Tsai
  • Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
    Publication number: 20030109683
    Abstract: The present invention provides mutant proteins of steroid hormone receptors. These mutant proteins are useful in methods of distinguishing a steroid hormone receptor antagonist from a steroid hormone receptor agonist. The present invention also provides plasmids containing mutated steroid hormone receptor proteins and cells transfected with those plasmids. In addition, the present invention provides methods for determining whether a compound is a steroid hormone receptor antagonist or agonist. Also, the present invention provides methods of determining endogenous ligands for steroid hormone receptors. The invention further provides a molecular switch protein for regulating expression in gene therapy.
    Type: Application
    Filed: April 16, 2002
    Publication date: June 12, 2003
    Applicants: Baylor College of Medicine, Valentis, Inc.
    Inventors: Bert W. O'Malley, Ming-Jer Tsai, Sophia Y. Tsai, Harry C. Ledebur, Yaolin Wang, Joseph D. Kittle
  • Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
    Publication number: 20020182698
    Abstract: The present invention provides mutant proteins of steroid hormone receptors. These mutant proteins are useful in methods of distinguishing a steroid hormone receptor antagonist from a steroid hormone receptor agonist. The present invention also provides plasmids containing mutated steroid hormone receptor proteins and cells transfected with those plasmids. In addition, the present invention provides methods for determining whether a compound is a steroid hormone receptor antagonist or agonist. Also, the present invention provides methods of determining endogenous ligands for steroid hormone receptors. The invention further provides a molecular switch protein for regulating expression in gene therapy.
    Type: Application
    Filed: April 16, 2002
    Publication date: December 5, 2002
    Applicant: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Ming-Jer Tsai, Sophia Y. Tsai, Harry C. Ledebur, Yaolin Wang, Joseph D. Kittle
  • Modified steroid hormones for gene therapy and methods for their use
    Publication number: 20020147327
    Abstract: The present invention provides modified proteins of steroid hormone receptors. These mutated proteins are useful as gene medicines. In particular, these mutated proteins are useful for regulating expression of genes in gene therapy. In addition, the present invention provides plasmids encoding for the desired mutated steroid hormone receptor proteins, as well as cells transfected with those plasmids.
    Type: Application
    Filed: July 25, 2001
    Publication date: October 10, 2002
    Inventors: Bert W. O'Malley, Ming-Jer Tsai, Sophia Y. Tsai, Harry C. Ledebur, Yaolin Wang, Joseph D. Kittle
  • Plasmid encoding a modified steroid hormone
    Patent number: 6416998
    Abstract: The present invention provides mutated proteins of steroid hormone receptors. These mutated proteins are useful as gene medicines. In particular, these mutated proteins are useful for regulating expression of genes in gene therapy. In addition, the present invention provides plasmids encoding for the desired mutated steroid hormone receptor proteins, as well as cells transfected with those plasmids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 9, 2002
    Assignees: Baylor College of Medicine, Valentis, Inc.
    Inventors: Bert W. O'Malley, Ming-Jer Tsai, Harry C. Ledebur, Jr., Joseph D. Kittle, Jr.
  • Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
    Patent number: 6228614
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product. The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: May 8, 2001
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Antisense modulation of SRA expression
    Patent number: 6107092
    Abstract: Antisense compounds, compositions and methods are provided for modulating the function or amount of SRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to SRA or nucleic acids encoding SRA. Methods of using these compounds for modulation of SRA levels and for treatment of diseases associated with SRA are provided.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: August 22, 2000
    Assignees: Isis Pharmaceuticals Inc., Baylor College of Medicine
    Inventors: Lex M. Cowsert, C. Frank Bennett, Bert W. O'Malley
  • Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
    Patent number: 6100054
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: August 8, 2000
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
    Patent number: 6080559
    Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: June 27, 2000
    Assignee: Agennix, Inc.
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley
  • Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in aspergillus
    Patent number: 5955316
    Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: September 21, 1999
    Assignee: Agennix, Inc.
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley
  • Screening system for identifying compounds that regulate steroid and orphan receptors mediation of DNA transcription
    Patent number: 5945279
    Abstract: A tissue culture screening system to monitor a transcriptional response treated by a chemical signal interacting with a plasma membrane receptor is provided. The tissue culture screening system includes a cell line containing a membrane receptor, a target gene and a specific receptor selected from the group consisting of a steroid receptor, a vitamin receptor and an orphan receptor. The specific receptor regulates transcription of the target gene. Any of the target gene membrane receptor or specific receptor can be introduced into the cell by an expression vector. In addition to the screening system there is also provided assays for identifying test compounds and chemical signals that regulate transcription or are potential agonist or antagonist neurotransmitters or which regulate indirectly by a membrane receptor binding or regulate transription in the absence of a steroid, vitamin or orphan ligand. There is further provided kits for the assays.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: August 31, 1999
    Assignee: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Orla M. Conneely, Ronan F. Power
  • Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
    Patent number: 5935934
    Abstract: The present invention provides mutant proteins of steroid hormone receptors. These mutant proteins are useful in methods of distinguishing a steroid hormone receptor antagonist from a steroid hormone receptor agonist. The present invention also provides plasmids containing mutated steroid hormone receptor proteins and cells transfected with those plasmids. In addition, the present invention provides methods for determining whether a compound is a steroid hormone receptor antagonist or agonist. Also, the present invention provides methods of determining endogenous ligands for steroid hormone receptors. The invention further provides a molecular switch for regulating expression in gene therapy and methods of employing the molecular switch in humans, animals, transgenic animals and plants.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: August 10, 1999
    Assignee: Baylor College of Medicine
    Inventors: Elisabetta Vegeto, Donald P. McDonnell, Bert W. O'Malley, William T. Schrader, Ming-Jer Tsai
  • Expression vector systems and method of use
    Patent number: 5925564
    Abstract: This invention relates to gene therapy by using vectors which encode stable MRNA and methods of using such vectors. In particular, this invention relates to vectors which establish controlled expression of recombinant genes within tissues at certain levels. The vector includes a 5' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a 3' flanking region including a 3' UTR and/or 3' NCR which stabilizes mRNA expressed from the nucleic acid cassette, and a linker which connects the 5' flanking region to a nucleic acid sequence. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. The 3' flanking region is 3' to the position for inserting the nucleic acid cassette. The expression vectors of the present invention can also be regulated by a regulatory system and/or constructed with a coating.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 20, 1999
    Assignee: Baylor College of Medicine
    Inventors: Robert J. Schwartz, Franco J. DeMayo, Bert W. O'Malley
  • Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
    Patent number: 5874534
    Abstract: The present invention provides mutant proteins of steroid hormone receptors. These mutant proteins are useful in methods of distinguishing a steroid hormone receptor antagonist from a steroid hormone receptor agonist. The present invention also provides plasmids containing mutated steroid hormone receptor proteins and cells transfected with those plasmids. In addition, the present invention provides methods for determining whether a compound is a steroid hormone receptor antagonist or agonist. Also, the present invention provides methods of determining endogenous ligands for steroid hormone receptors. The invention further provides a molecular switch for regulating expression in gene therapy and methods of employing the molecular switch in humans, animals, transgenic animals and plants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 23, 1999
    Assignee: Baylor College of Medicine
    Inventors: Elisabetta Vegeto, Donald P. McDonnell, Bert W. O'Malley, William T. Schrader, Ming-Jer Tsai
  • Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
    Patent number: 5849881
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: December 15, 1998
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Screening system and assay for identifying compounds that regulate steroid and orphan receptors mediation of DNA transcription
    Patent number: 5834213
    Abstract: A tissue culture screening system to monitor a transcriptional response treated by a chemical signal interacting with a plasma membrane receptor is provided. The tissue culture screening system includes a cell line containing a membrane receptor, a target gene and a specific receptor selected from the group consisting of a steroid receptor, a vitamin receptor and an orphan receptor. The specific receptor regulates transcription of the target gene. Any of the target gene membrane receptor or specific receptor can be introduced into the cell by an expression vector. In addition to the screening system there is also provided assays for identifying test compounds and chemical signals that regulate transcription or are potential agonist or antagonist neurotransmitters or which regulate indirectly by a membrane receptor binding or regulate transcription in the absence of a steroid, vitamin or orphan ligand. There is further provided kits for the assays.
    Type: Grant
    Filed: October 1, 1993
    Date of Patent: November 10, 1998
    Assignee: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Orla M. Conneely, Ronan F. Power
  • Tranformation of cells associated with fluid spaces
    Patent number: 5792751
    Abstract: This invention relates to the transfer and expression of genes in cells associated with fluid spaces, such as follicles of the thyroid, the synovium of the joint, the vitreous of the eye and the inner or middle ear. Formulated DNA expression vectors comprising a gene are introduced with or without formulation elements directly into a fluid space under conditions in which the cells associated with the fluid space can incorporate the formulated DNA expression vector and express the transformed gene.
    Type: Grant
    Filed: January 21, 1994
    Date of Patent: August 11, 1998
    Assignee: Baylor College of Medicine
    Inventors: Fred D. Ledley, Bert W. O'Malley, Jr.
  • Somatic gene therapy to cells associated with fluid spaces
    Patent number: 5770580
    Abstract: This invention relates to somatic gene therapy to cells associated with fluid spaces, such as follicles of the thyroid, the synovium of the joint, the vitreous of the eye and the inner or middle ear. Formulated DNA expression vectors are introduced with or without formulation elements into fluid spaces under conditions in which cells associated with the fluid space can incorporate the formulated DNA expression vector. Formulated DNA expression-mediated gene therapy allows treatment of diseases involving cells associated with fluid spaces.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: June 23, 1998
    Assignee: Baylor College of Medicine
    Inventors: Fred D. Ledley, Bert W. O'Malley, Jr.